1-4 of 4
Jeremy Bechelli
Close
Sort by
Journal Articles

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Jane L. Liesveld, MD, Kristen O'Dwyer, MD, Michael W. Becker, MD, Deborah Mulford, MD, Alison Walker, MD, Rui Chen, PhD, Jeremy Bechelli, MS, Karen Rosell, BS, Craig T. Jordan, PhD, Mohammad Minhajuddin, PhD, Gordon L. Phillips, II, MD
Journal: Blood
Blood (2012) 120 (21): 3549.
https://doi.org/10.1182/blood.V120.21.3549.3549
Published: 2012
Journal Articles

Activity and Cytotoxicity of Algae Extracts On Normal and Leukemic Hematopoietic Cells.

Jeremy Bechelli, M.S., Karen Rosell, BS, Myra Coppage, PhD, Jane Liesveld, MD
Journal: Blood
Blood (2009) 114 (22): 4815.
https://doi.org/10.1182/blood.V114.22.4815.4815
Published: 2009
Journal Articles

Proteasome Inhibitor Combination with Cytarabine or Arsenic Trioxide Can Potentiate Apoptosis in AML Cells.

Jane L. Liesveld, MD, Camille N. Abboud, MD, Chaohui Lu, Jeremy Bechelli, Karen Rosell, Gordon Phillips, MD, Jeffrey E. Lancet, MD
Journal: Blood
Blood (2005) 106 (11): 4464.
https://doi.org/10.1182/blood.V106.11.4464.4464
Published: 2005
Journal Articles

The CXCR4 Antagonist, AMD3100, Inhibits AML Transmigratory Activity but Does Not Alter Blast Proliferation or Survival.

Jane L. Liesveld, MD, Jeffrey E. Lancet, MD, Karen E. Rosell, BS, Jeremy Bechelli, BS, Camille N. Abboud, MD, Gordon L. Phillips, II, MD
Journal: Blood
Blood (2004) 104 (11): 2881.
https://doi.org/10.1182/blood.V104.11.2881.2881
Published: 2004